Should ustekinumab really be used as first-line biological therapy in pityriasis rubra pilaris?
Author:
Publisher
Wiley
Subject
Dermatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2133.2010.09942.x/fullpdf
Reference5 articles.
1. Treatment of pityriasis rubra pilaris with ustekinumab;Wohlrab;Br J Dermatol,2010
2. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series;Garcovich;J Eur Acad Dermatol Venereo,2010
3. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases;Elliott;Ann N Y Acad Sci,2009
4. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients;Prescrire Int,2009
5. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy;Müller;J Am Acad Dermatol,2008
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Is risankizumab effective in the treatment of pityriasis rubra pilaris?;Dermatologic Therapy;2021-08-31
2. Eficacia y seguridad de ustekinumab en el tratamiento de la pitiriasis rubra pilaris tipo 1 refractaria. Seguimiento durante 5 años;Piel;2020-03
3. Management of refractory pityriasis rubra pilaris: challenges and solutions;Clinical, Cosmetic and Investigational Dermatology;2017-11
4. Die tägliche Herausforderung – Pityriasis rubra pilaris;Fortschritte der praktischen Dermatologie und Venerologie 2012;2013
5. Emerging dermatological and systemic applications of ustekinumab: beyond its clinical use in psoriasis;Clinical, Cosmetic and Investigational Dermatology;2012-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3